In recent years, with the rapid development of molecular biology and biotechnology, cancer treatment has undergone a profound transformation. Moving beyond the traditional three pillars—surgery, radiotherapy, and chemotherapy—the field is entering a new era centered on precision targeted therapy, immunotherapy, and cell therapy. Globally,innovative drugs continue to emerge, and treatment paradigms are shifting from “broad-spectrum killing” to a model of “precision targeting + systemic regulation.”
Targeted Therapy: From Single Inhibition to Precision Drug Delivery
Targeted therapy is a cornerstone of precision oncology. Drugs targeting molecules such as EGFR and HER2 have already demonstrated significant efficacy across various cancers. However, the emergence of drug resistance has exposed the limitations of single-target approaches.
In this context, antibody-drug conjugates (ADCs) have become a major breakthrough. By combining antibodies with cytotoxic agents, ADCs enable precise delivery of drugs directly to tumor cells. For example, Disitamab Vedotin not only recognizes tumor cells but also exerts a “bystander effect,” killing surrounding cancer cells. This mechanism significantly enhances therapeutic efficacy while reducing damage to normal tissues.
It is evident that targeted therapy is evolving from “signal pathway inhibition” to “precision drug delivery systems.”
Immunotherapy: Activating the Body’s Own Anti-Cancer Power
The rise of immunotherapy is widely regarded as one of the most revolutionary advances in oncology. Immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, are now widely used in cancers including lung cancer and melanoma.
For instance, Tislelizumab enhances immune responses by optimizing its Fc structure to reduce T-cell clearance, while Toripalimab achieves differentiated immune modulation through a unique epitope design. Unlike traditional therapies, these drugs do not directly kill tumor cells but instead “awaken” the immune system, enabling T cells to recognize and attack cancer.
Moreover, immunotherapy is shifting from monotherapy to combination strategies—such as pairing with chemotherapy, targeted therapy, or ADCs—to further improve outcomes. This “combination approach” is becoming a key direction in clinical practice, signaling a move from isolated breakthroughs to systemic application.
Bispecific Antibodies: A New Paradigm of Multi-Target Synergy
Bispecific antibodies are one of the fastest-growing frontiers in oncology. Their key advantage lies in the ability to simultaneously recognize two different targets, enabling more precise and efficient treatment.
For example, DLL3/CD3 bispecific antibodies work by linking tumor cells with T cells, directing immune cells to specifically eliminate cancer. This mechanism bypasses the need for traditional antigen presentation, improving efficiency and offering new possibilities for treating solid tumors.
Currently, bispecific antibody technology is expanding from hematologic malignancies into solid tumors, becoming a global R&D hotspot. This trend highlights the increasing importance of multi-target synergy and systemic regulation in future cancer therapies.
Cell Therapy: The Ultimate Direction of Personalized Medicine
CAR-T cell therapy represents a major advancement in cell-based treatments. By genetically engineering a patient’s own T cells to recognize and destroy tumor cells, CAR-T has achieved remarkable success in hematologic cancers.
However, challenges remain in solid tumors, including complex tumor microenvironments and difficulty in target selection. To address these issues, researchers are exploring next-generation approaches such as CAR-NK and TCR-T therapies.
Looking ahead, as technologies continue to mature, cell therapy is expected to become a central component of personalized medicine, offering new hope for patients with refractory cancers.
Conclusion
Overall, cancer treatment is entering a new stage characterized by precision, personalization, and system integration. From targeted therapy to immunotherapy, from bispecific antibodies to cell therapy, each technological advancement continues to expand the boundaries of cancer care.
Looking forward, several key trends are emerging:
● Continuous technological innovation, particularly in ADCs, bispecific antibodies, and cell therapies
● A shift from single-drug approaches to multi-modality combination strategies
● Parallel development of globalization and localization, accelerating access to innovative drugs
More importantly, the competitive landscape of the pharmaceutical industry is evolving. Companies can no longer rely solely on a single product but must build comprehensive capabilities spanning R&D, clinical development, manufacturing, supply chain, and commercialization.
In this process, alongside continuous scientific breakthroughs, companies with strong global resource integration capabilities—such as Dengyue Pharma—play a crucial role in ensuring that innovative medicines reach patients more efficiently and safely. As technology and industry ecosystems continue to advance, humanity is poised to make even greater strides in the fight against cancer.
